Activity Provided By:

This CME-certified enduring activity is jointly provided by Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation.

Shaping the Future of Myeloma Treatment

Overview / Abstract:	To help hematologist-oncologists keep pace with new advancements in multiple myeloma therapeutic regimens and management strategies, Shaping the Future of Myeloma Treatment features a roundtable discussion in which a panel of myeloma experts addresses a number of key clinical topics. Learners who participate in these activities will be expected to improve their ability to individualize treatment plans, based on genomics and risk stratification, to achieve durable remission while minimizing toxicity.
Expiration	Jul 11, 2020
Discipline(s)	Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME
Format	Online
Credits / Hours	Penn State College of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)^TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accreditation	This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Presenters / Authors / Faculty	Ivan M. Borrello, MD Associate Professor of Oncology Johns Hopkins University Baltimore, Maryland Sergio A. Giralt, MD Chief Attending, BMT Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell Medical College New York, New York Joshua R. Richter, MD Assistant Professor of Medicine Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai New York, New York
Activity Specialities / Related Topics	Oncology / Cancer / Radiation Therapy, Internal Medicine, Hematology
Sponsors / Supporters / Grant Providers	Support for this activity has been provided through educational grants from AbbVie Inc., Celgene Corporation, and Takeda Oncology.
Keywords / Search Terms	RedMedEd, MMRF, MM, mulitple myeloma, hematology, oncology, CME, free, roundtable, minimal residual disease, MRD, risk stratification, cytogenetics, genomics, clinical trials, immunotherapy, relapsed, refractory, FISH, gene-expression, mSMART, imaging, MyDRUG, checkpoint inhibitors, ASCT

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map